Topical tacrolimus for the treatment of localized, idiopathic, newly diagnosed pyoderma gangrenosum
Authors:
- 5 October 2009
- journal article
- research article
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 21 (3) , 140-143
Abstract
Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis which may present in a classic ulcerative form or in atypical bullous, vegetative or pustular variants. It can be associated with several disorders or be idiopathic. Although systemic immunosuppressants remain the choice therapy for most cases of PG, a local approach should be considered in localized disease. Recently, topical tacrolimus has successfully been used as an off-label drug in localized PG. In the present study, five patients with localized, idiopathic, newly diagnosed PG were treated with topical tacrolimus monotherapy. Localized PG was defined as disease involving no more than 5% of the body surface area and presenting with no more than three lesions. Cultures performed on PG lesions both before and during tacrolimus treatment were negative. In all five patients complete remission was achieved within a mean time of 6 weeks and no relapses occurred; in three cases, tacrolimus was discontinued, while the remaining two patients were applying the drug as maintenance therapy at the time of writing. Thus, we suggest that topical tacrolimus monotherapy could represent the first-line treatment for PG that fulfils the following criteria: localized disease, idiopathic form and recent onset with negative microbiological tests on PG lesions.Keywords
This publication has 17 references indexed in Scilit:
- Widespread idiopathic pyoderma gangrenosum evolved from ulcerative to vegetative type: a 10-year history with a recent response to infliximabClinical and Experimental Dermatology, 2008
- Fatal Bullous Pyoderma Gangrenosum in a Patient with KlinefelterActa Dermato-Venereologica, 2008
- Penile Pyoderma Gangrenosum Treated With Topical TacrolimusArchives of Dermatology, 2005
- Topical tacrolimus (FK506) in the treatment of recalcitrant parastomal pyoderma gangrenosum associated with Crohn's disease: report of two casesColorectal Disease, 2004
- Efficacy and systemic absorption of topical tacrolimus used in pyoderma gangrenosumBritish Journal of Dermatology, 2004
- Pyoderma gangrenosum: a reviewJournal of Cutaneous Pathology, 2003
- Tacrolimus: a review of its use for the management of dermatosesJournal of the European Academy of Dermatology and Venereology, 2002
- Combination oral and topical tacrolimus in therapy-resistant pyoderma gangrenosumBritish Journal of Dermatology, 1999
- Topical tacrolimus for pyoderma gangrenosumThe Lancet, 1998
- FK506 in the treatment of inflammatory skin disease: promises and perspectivesImmunology Today, 1996